메뉴 건너뛰기




Volumn 3, Issue SUPPL.1, 2009, Pages

On-treatment monitoring of HBV DNA levels: Predicting response and resistance to oral antiviral therapy at week 24 versus week 48

Author keywords

Antiviral therapy; Chronic hepatitis B; Treatment monitoring

Indexed keywords


EID: 84898013275     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-009-9143-0     Document Type: Review
Times cited : (8)

References (45)
  • 1
    • 51049107683 scopus 로고    scopus 로고
    • Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update
    • for the Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver
    • Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al., for the Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008;2:263-283
    • (2008) Hepatol Int , vol.2 , pp. 263-283
    • Liaw, Y.F.1    Leung, N.2    Kao, J.H.3    Piratvisuth, T.4    Gane, E.5    Han, K.H.6
  • 2
    • 33847701354 scopus 로고    scopus 로고
    • Chronic hepatitis B
    • DOI 10.1002/hep.21513
    • Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-539 (Pubitemid 46374607)
    • (2007) Hepatology , vol.45 , Issue.2 , pp. 507-539
    • Lok, A.S.F.1    McMahon, B.J.2
  • 3
    • 58149296156 scopus 로고    scopus 로고
    • EASL clinical practice guidelines: Management of chronic hepatitis B
    • European Association for the Study of the Liver
    • European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-242
    • (2009) J Hepatol , vol.50 , pp. 227-242
  • 4
    • 19544391413 scopus 로고    scopus 로고
    • Lamivudine for patients with chronic hepatitis B and advanced liver disease
    • for the Cirrhosis Asian Lamivudine Multicentre Study Group
    • Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al., for the Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531
    • (2004) N Engl J Med , vol.351 , pp. 1521-1531
    • Liaw, Y.F.1    Sung, J.J.2    Chow, W.C.3    Farrell, G.4    Lee, C.Z.5    Yuen, H.6
  • 6
    • 58649096155 scopus 로고    scopus 로고
    • 2-Year GLOBE trial results: Telbivudine is superior to lamivudine in patients with chronic hepatitis B
    • for the GLOBE Study Group
    • Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al., for the GLOBE Study Group. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136:486-495
    • (2009) Gastroenterology , vol.136 , pp. 486-495
    • Liaw, Y.F.1    Gane, E.2    Leung, N.3    Zeuzem, S.4    Wang, Y.5    Lai, C.L.6
  • 7
    • 67349178133 scopus 로고    scopus 로고
    • Baseline characteristics and early on-treatment response predict the outcomes of 2 years telbivudine treatment of chronic hepatitis B
    • Zeuzem S, Gane E, Liaw YK, Lim SG, DiBisceglie A, Buti M, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years telbivudine treatment of chronic hepatitis B. J Hepatol 2009;51:11-20
    • (2009) J Hepatol , vol.51 , pp. 11-20
    • Zeuzem, S.1    Gane, E.2    Liaw, Y.K.3    Lim, S.G.4    DiBisceglie, A.5    Buti, M.6
  • 8
    • 79959590320 scopus 로고    scopus 로고
    • Bristol Myers-Squibb. Available from: Accessed 1 June 2009
    • Bristol Myers-Squibb. Entecavir AVDAC briefing document; 2005. Available from: http://www.fda.gov/OHRMS/DOCKETS/ac/05/briefing/2005-4094B1-01- BristolMyersSquibb-entecavir.pdf. Accessed 1 June 2009
    • (2005) Entecavir AVDAC Briefing Document
  • 9
    • 77955981141 scopus 로고    scopus 로고
    • Entecavir induced HBV DNA suppression at 12 weeks in treatment-naive patients with chronic hepatitis B is a good predictive factor for virological response at 48 weeks
    • Abstract No.: 969
    • Lee HW, Kim HJ, Kim MH, Kim KA, Lee JS, Sul HR, et al. Entecavir induced HBV DNA suppression at 12 weeks in treatment-naive patients with chronic hepatitis B is a good predictive factor for virological response at 48 weeks. Hepatology 2008;48(Suppl):741A. Abstract No.: 969
    • (2008) Hepatology , vol.48 , Issue.SUPPL.
    • Lee, H.W.1    Kim, H.J.2    Kim, M.H.3    Kim, K.A.4    Lee, J.S.5    Sul, H.R.6
  • 10
    • 59149090874 scopus 로고    scopus 로고
    • On-treatment monitoring of adefovir therapy in chronic hepatitis B: Virologic response can be assessed at 24 weeks
    • Reijnders JG, Leemans WF, Hansen BE, Pas SD, de Man RA, Schutten M, et al. On-treatment monitoring of adefovir therapy in chronic hepatitis B: virologic response can be assessed at 24 weeks. J Viral Hepat 2009;16:113-120
    • (2009) J Viral Hepat , vol.16 , pp. 113-120
    • Reijnders, J.G.1    Leemans, W.F.2    Hansen, B.E.3    Pas, S.D.4    De Man, R.A.5    Schutten, M.6
  • 11
    • 0035212206 scopus 로고    scopus 로고
    • Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy
    • DOI 10.1002/jmv.2087
    • Zöllner B, Schäfer P, Feucht HH, Schröter M, Petersen J, Laufs R. Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy. J Med Virol 2001;65:659-663 (Pubitemid 33135092)
    • (2001) Journal of Medical Virology , vol.65 , Issue.4 , pp. 659-663
    • Zollner, B.1    Schfer, P.2    Feucht, H.-H.3    Schroter, M.4    Petersen, J.5    Laufs, R.6
  • 12
    • 0032751727 scopus 로고    scopus 로고
    • Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine
    • Gauthier J, Bourne EJ, Lutz MW, Crowther LM, Dienstag JL, Brown NA, et al. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J Infect Dis 1999;180:1757-1762
    • (1999) J Infect Dis , vol.180 , pp. 1757-1762
    • Gauthier, J.1    Bourne, E.J.2    Lutz, M.W.3    Crowther, L.M.4    Dienstag, J.L.5    Brown, N.A.6
  • 13
    • 0034802516 scopus 로고    scopus 로고
    • Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy
    • DOI 10.1053/jhep.2001.27563
    • Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001;34:785-791 (Pubitemid 32928004)
    • (2001) Hepatology , vol.34 , Issue.4 I , pp. 785-791
    • Yuen, M.-F.1    Sablon, E.2    Hui, C.-K.3    Yuan, H.-J.4    Decraemer, H.5    Lai, C.-L.6
  • 14
    • 48249091883 scopus 로고    scopus 로고
    • Prediction of long-term maintenance of virologic response during lamivudine treatment in HBeAg negative chronic hepatitis B
    • Hadziyannis A, Mitsoula PV, Hadziyannis SJ. Prediction of long-term maintenance of virologic response during lamivudine treatment in HBeAg negative chronic hepatitis B. Hepatology 2007;46(Suppl):667A
    • (2007) Hepatology , vol.46 , Issue.SUPPL.
    • Hadziyannis, A.1    Mitsoula, P.V.2    Hadziyannis, S.J.3
  • 15
    • 61849114013 scopus 로고    scopus 로고
    • Factors affecting response to adefovir treatment in patients with chronic hepatitis B and lamivudine resistance
    • Pritchett S, Wong DK, Yim C, Mazzulli T, Heathcote EJ. Factors affecting response to adefovir treatment in patients with chronic hepatitis B and lamivudine resistance. Hepatology 2007; 46(Suppl):675A
    • (2007) Hepatology , vol.46 , Issue.SUPPL.
    • Pritchett, S.1    Wong, D.K.2    Yim, C.3    Mazzulli, T.4    Heathcote, E.J.5
  • 16
    • 39149122593 scopus 로고    scopus 로고
    • A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg positive chronic hepatitis B (CHB): Study GS-US-174-0103
    • Abstract No.: LB7
    • Heathcote EJ, Gane E, DeMan R, Lee S, Flisiak R, Manns MP, et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg positive chronic hepatitis B (CHB): study GS-US-174-0103. Hepatology 2007;46:861A. Abstract No.: LB7
    • (2007) Hepatology , vol.46
    • Heathcote, E.J.1    Gane, E.2    DeMan, R.3    Lee, S.4    Flisiak, R.5    Manns, M.P.6
  • 19
    • 60349129272 scopus 로고    scopus 로고
    • Chronic hepatitis B: Early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides
    • Nguyen MH, Keeffe EB. Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides. J Viral Hepat 2009;16:149-155
    • (2009) J Viral Hepat , vol.16 , pp. 149-155
    • Nguyen, M.H.1    Keeffe, E.B.2
  • 20
    • 61849132825 scopus 로고    scopus 로고
    • On-treatment outcome prediction and adjustment during chronic hepatitis B therapy: Now and future
    • Liaw YF. On-treatment outcome prediction and adjustment during chronic hepatitis B therapy: now and future. Antivir Ther 2009;14:13-22
    • (2009) Antivir Ther , vol.14 , pp. 13-22
    • Liaw, Y.F.1
  • 21
    • 65449136656 scopus 로고    scopus 로고
    • Diagnosis, management, and treatment of hepatitis C: An update
    • for the American Association for the Study of Liver Diseases
    • Ghany MG, Strader DB, Thomas DL, Seeff LB, for the American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-1374
    • (2009) Hepatology , vol.49 , pp. 1335-1374
    • Ghany, M.G.1    Strader, D.B.2    Thomas, D.L.3    Seeff, L.B.4
  • 22
    • 34247216563 scopus 로고    scopus 로고
    • Asian Pacific Association for the Study of the Liver consensus statements of the diagnosis, management and treatment of hepatitis C virus infection
    • Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party
    • Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party. Asian Pacific Association for the Study of the Liver consensus statements of the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007;22:615-633
    • (2007) J Gastroenterol Hepatol , vol.22 , pp. 615-633
  • 23
    • 50649112802 scopus 로고    scopus 로고
    • Treatment predictors of a sustained virologic response in hepatitis B and C
    • Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008;49:634-651
    • (2008) J Hepatol , vol.49 , pp. 634-651
    • Kau, A.1    Vermehren, J.2    Sarrazin, C.3
  • 24
    • 33645109452 scopus 로고    scopus 로고
    • Quantitative HBV DNA levels as an early predictor of nonresponse in chronic HBe-antigen positive hepatitis B patients treated with interferon-alpha
    • van der Eijk AA, Niesters HG, Hansen BE, Heijtink RA, Janssen HLA, Schalm SW, et al. Quantitative HBV DNA levels as an early predictor of nonresponse in chronic HBe-antigen positive hepatitis B patients treated with interferon-alpha. J Viral Hepatol 2006;13:96-103
    • (2006) J Viral Hepatol , vol.13 , pp. 96-103
    • Van Der Eijk, A.A.1    Niesters, H.G.2    Hansen, B.E.3    Heijtink, R.A.4    Janssen, H.L.A.5    Schalm, S.W.6
  • 26
    • 34249090519 scopus 로고    scopus 로고
    • Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: A double-blind, placebo-controlled trial
    • Chan HL, Wang H, Niu J, Chim AM, Sung JJ. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir Ther 2007;12:345-353 (Pubitemid 46787979)
    • (2007) Antiviral Therapy , vol.12 , Issue.3 , pp. 345-353
    • Chan, H.L.-Y.1    Wang, H.2    Niu, J.3    Chim, A.M.-L.4    Sung, J.J.-Y.5
  • 28
    • 23244453590 scopus 로고    scopus 로고
    • A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B
    • DOI 10.1016/j.gastro.2005.05.053, PII S0016508505010784
    • Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW et al., for the Telbivudine Phase II Investigator Group. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005;129:528-536 (Pubitemid 41096641)
    • (2005) Gastroenterology , vol.129 , Issue.2 , pp. 528-536
    • Lai, C.-L.1    Leung, N.2    Teo, E.-K.3    Tong, M.4    Wong, F.5    Hann, H.-W.6    Han, S.7    Poynard, T.8    Myers, M.9    Chao, G.10    Lloyd, D.11    Brown, N.A.12
  • 29
    • 37749021636 scopus 로고    scopus 로고
    • Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response
    • Yuen MF, Fong DY, Wong DK, Yuen JC, Fung J, Lai CL. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology 2007;46:1695-1703
    • (2007) Hepatology , vol.46 , pp. 1695-1703
    • Yuen, M.F.1    Fong, D.Y.2    Wong, D.K.3    Yuen, J.C.4    Fung, J.5    Lai, C.L.6
  • 30
    • 70350133508 scopus 로고    scopus 로고
    • Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naïve patients
    • Abstract No.: 20
    • Tenney DJ, Pokornowski KA, Rose RE, Baldick CJ, Eggers BJ, Fang J, et al. Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naïve patients. J Hepatol 2009; 50(Suppl):S10. Abstract No.: 20
    • (2009) J Hepatol , vol.50 , Issue.SUPPL.
    • Tenney, D.J.1    Pokornowski, K.A.2    Rose, R.E.3    Baldick, C.J.4    Eggers, B.J.5    Fang, J.6
  • 31
    • 66149115173 scopus 로고    scopus 로고
    • Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy
    • Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009;49:1503-1514
    • (2009) Hepatology , vol.49 , pp. 1503-1514
    • Tenney, D.J.1    Rose, R.E.2    Baldick, C.J.3    Pokornowski, K.A.4    Eggers, B.J.5    Fang, J.6
  • 36
    • 65849220728 scopus 로고    scopus 로고
    • Week 24 suppression of HBV in entecavir-treated chronic hepatitis B patients in whom lamivudine treatment failed is associated with efficacy at week 48
    • Ma H, Ren JB, Li HY, Wang Y, Wang RL, Liang L, et al. Week 24 suppression of HBV in entecavir-treated chronic hepatitis B patients in whom lamivudine treatment failed is associated with efficacy at week 48. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2007;21:102-104
    • (2007) Zhonghua Shi Yan He Lin Chuang Bing du Xue Za Zhi , vol.21 , pp. 102-104
    • Ma, H.1    Ren, J.B.2    Li, H.Y.3    Wang, Y.4    Wang, R.L.5    Liang, L.6
  • 37
    • 77149141508 scopus 로고    scopus 로고
    • Prolonged efficacy and safety of 3 years of continuous telbivudine treatment in pooled data from GLOBE and 015 studies in chronic hepatitis B patients
    • Abstract No.: 911
    • Hsu CW, Chen YC, Liaw YF, Gane E, Manns M, Zeuzem S, et al. Prolonged efficacy and safety of 3 years of continuous telbivudine treatment in pooled data from GLOBE and 015 studies in chronic hepatitis B patients. J Hepatol 2009;50:S331. Abstract No.: 911
    • (2009) J Hepatol , vol.50
    • Hsu, C.W.1    Chen, Y.C.2    Liaw, Y.F.3    Gane, E.4    Manns, M.5    Zeuzem, S.6
  • 38
  • 40
    • 58949087420 scopus 로고    scopus 로고
    • Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir
    • Leung N, Peng CY, Hann HW, Sollano J, Lao-Tan J, Hsu CW, et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology 2009;49:72-79
    • (2009) Hepatology , vol.49 , pp. 72-79
    • Leung, N.1    Peng, C.Y.2    Hann, H.W.3    Sollano, J.4    Lao-Tan, J.5    Hsu, C.W.6
  • 41
    • 27144488889 scopus 로고    scopus 로고
    • Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB)
    • Abstract No.: 36
    • Locarnini S, Qi X, Arterburn S, Snow A, Brosgart CL, Currie G, et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB). J Hepatol 2005;42 (Suppl):17. Abstract No.: 36
    • (2005) J Hepatol , vol.42 , Issue.SUPPL. , pp. 17
    • Locarnini, S.1    Qi, X.2    Arterburn, S.3    Snow, A.4    Brosgart, C.L.5    Currie, G.6
  • 43
    • 45549103233 scopus 로고    scopus 로고
    • Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-positive chronic hepatitis B: Week 72 TDF data and week 24 adefovir dipivoxil switch data (study 103)
    • Abstract No.: 72
    • Heathcote J, George S, Gordon JP, Bronowicki J, Sperl R, Williams P, et al. Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-positive chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (study 103). J Hepatol 2008;48:S32. Abstract No.: 72
    • (2008) J Hepatol , vol.48
    • Heathcote, J.1    George, S.2    Gordon, J.P.3    Bronowicki, J.4    Sperl, R.5    Williams, P.6
  • 44
    • 45549094638 scopus 로고    scopus 로고
    • Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-negative chronic hepatitis B: Week 72 TDF data and week 24 adefovir dipivoxil switch study (study 102)
    • Abstract No.: 57
    • Marcellin P, Jacobson I, Habersetzer F, Senturk H, Andreone P, Moyes C, et al. Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-negative chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch study (study 102). J Hepatol 2008;48:S26. Abstract No.: 57
    • (2008) J Hepatol , vol.48
    • Marcellin, P.1    Jacobson, I.2    Habersetzer, F.3    Senturk, H.4    Andreone, P.5    Moyes, C.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.